Opendata, web and dolomites


Drug CandIdates ScreenINg

Total Cost €


EC-Contrib. €






Project "DeCISIoN" data sheet

The following table provides information about the project.


Organization address
address: GALLILEIWEG 8
city: LEIDEN
postcode: 2333 BD

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Project website
 Total cost 3˙228˙570 €
 EC max contribution 3˙228˙570 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2016-2017
 Funding Scheme SME-2
 Starting year 2016
 Duration (year-month-day) from 2016-07-01   to  2018-12-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NCARDIA BV NL (LEIDEN) coordinator 3˙228˙570.00


 Project objective

Pluriomics is an international Dutch/Belgian biotech company specialised in developing stem cell-based assays for cardiac safety pharmacology and drug discovery and development. Pluriomics developed a unique proprietary protocol to differentiate heart muscle cells derived from human induced pluripotent stem cells (hiPSCs). The company provides its customers with reliable cell technology systems to test potential drugs in the preclinical phase with high predictive value. Safety issues remains a key problem in drug development. This is amongst others emphasised by the case of AstraZeneca where 82% of pre-clinical and 62% of phase I project closures where related to safety issues. Out of the safety related failures the cardiovascular system is involved in 17% of the preclinical failures and 24% of the clinical failures. Examples of cardiovascular effects, include arrhythmias, hypertrophy, hypertension and reduced ventricular function, which may lead to increased cardiac risk and possibly death. Additional reasons for the decline in success rates are related to the lack of predictive models for early drug efficacy screening. Pluriomics has developed Pluricyte® Cardiomyocytes and integrated proprietary assay systems to overcome the abovementioned challenges. Enabling market uptake and distribution of cell technology based innovations can be challenging, with large scale production and development of regulatory compliant predictive models as main challenges. DeCISIoN will tackle these challenges and thus accelerate market uptake of their cardiac safety assays. DeCISIoN will take the next steps and deliver 1) an up-scaled and more cost-effective manufacturing process; 2) novel, validated, predictive high-throughput cardiac assays for further improved cardiac toxicity and drug efficacy testing and 3) a fully developed marketing and commercialisation strategy for the cardiac assays. As such, DeCISIoN will take Pluriomics' cardiac assays from TRL6 to TRL9.


year authors and title journal last update
List of publications.
2018 Petra Mulder, Tessa de Korte, Elena Dragicevic, Udo Kraushaar, Richard Printemps, Maria L.H. Vlaming, Stefan R. Braam, Jean-Pierre Valentin
Predicting cardiac safety using human induced pluripotent stem cell-derived cardiomyocytes combined with multi-electrode array (MEA) technology: A conference report
published pages: 36-42, ISSN: 1056-8719, DOI: 10.1016/j.vascn.2018.01.003
Journal of Pharmacological and Toxicological Methods 91 2019-07-19

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DECISION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DECISION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

PanCareFollowUp (2019)

PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregivers

Read More  

LEGACy (2019)

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Read More  

HAP2 (2020)

Host-targeted Approaches for the Prevention and the treatment of Hospital-Acquired Pneumonia

Read More